-
Mashup Score: 20Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5) - 1 day(s) ago
Axi-cel demonstrated durable responses in patients with FL and MZL after 3 years of follow-up.Elevated baseline total metabolic tumor volume and recent pri
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma - 1 day(s) ago
The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Source: www.ajmc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy - 1 day(s) ago
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3FDA Clears IND Application for SynKIR-310 Trial in R/R B-NHL - 4 day(s) ago
With the FDA clearance of an investigational new drug application for SynKIR-310, a phase 1 trial evaluating the agent in relapsed/refractory B-cell non-Hodgkin lymphomas will begin.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 69The CNS Relapse in T-Cell Lymphoma Index Predicts CNS Relapse in Patients with T- and NK-Cell Lymphomas - 4 day(s) ago
Key Points. Tumor histology and number of sites of extranodal involvement are prominent risk factors for CNS relapse.The CITI score is a validated risk mod
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 69The CNS Relapse in T-Cell Lymphoma Index Predicts CNS Relapse in Patients with T- and NK-Cell Lymphomas - 5 day(s) ago
Key Points. Tumor histology and number of sites of extranodal involvement are prominent risk factors for CNS relapse.The CITI score is a validated risk mod
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL - 7 day(s) ago
Acalabrutinib combination therapy elicits statistically significant improvement in progression-free survival for treatment-naive mantle cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif Department of Pediatric Oncology and Hematology, Bordeaux University hospital, Bordeaux Department of Pediatric Oncology
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 86
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5) https://t.co/6TQuphVvCF #lymsm https://t.co/ozl0W2zvNj